Alpelisib plus fulvestrant in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A

被引：2
|
作者：
Ciruelos, Eva M.
Lerebours, Florence
Rugo, Hope S.
Ruiz-Borrego, Manuel
Drullinsky, Pamela
Prat, Aleix
Bachelot, Thomas
Neven, Patrick
Park, Yeon Hee
Turner, Nicholas
Juric, Dejan
Gu, Ennan
Arce, Christina H.
Akdere, Murat
Chia, Stephen
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P1-18-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-18-03
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Alpelisib plus letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results
    Rugo, Hope S.
    Lerebours, Florence
    Juric, Dejan
    Turner, Nicholas
    Chia, Stephen
    Drullinsky, Pamela
    Prat, Aleix
    Villanueva Vazquez, Rafael
    Akdere, Murat
    Arce, Christina
    Shen, Yu-Ming
    Ciruelos, Eva
    CANCER RESEARCH, 2021, 81 (04)
  • [2] PIK3CA-mutated (mut) hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) plus aromatase inhibitor (AI): BYLieve study results.
    Rugo, Hope S.
    Lerebours, Florence
    Ciruelos, Eva
    Drullinsky, Pamela
    Borrego, Manuel Ruiz
    Neven, Patrick
    Park, Yeon Hee
    Prat, Aleix
    Bachelot, Thomas
    Juric, Dejan
    Turner, Nicholas C.
    Sophos, Nickolas
    Zarate, Juan Pablo
    Arce, Christina
    Shen, Yu-Ming
    Chia, Stephen K. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Alpelisib plus endocrine therapy (ET) in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study
    Juric, Dejan
    Turner, Nicholas
    Prat, Aleix
    Chia, Stephen
    Ciruelos, Eva M.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Lerebours, Florence
    Bachelot, Thomas
    Balbin, O. Alejandro
    Joshi, Mukta
    Roux, Estelle
    Arce, Christina H.
    Akdere, Murat
    Rugo, Hope S.
    CANCER RESEARCH, 2022, 82 (04)
  • [4] EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).
    De Laurentiis, Michelino
    Costa, Luis
    Gligorov, Joseph
    Knop, Ann
    Senkus-Konefka, Elzbieta
    Garcia-Saenz, Jose A.
    Schmid, Peter
    Heniquez, Aurelia
    Serra, Paolo
    Reising, Albert
    Kuemmel, Sherko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤6 mo or >6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve
    Chia, Stephen
    Ciruelos, Eva M.
    Rugo, Hope S.
    Lerebours, Florence
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Prat, Aleix
    Bachelot, Thomas
    Turner, Nicholas
    Gu, Ennan
    Arce, Christina
    Akdere, Murat
    Juric, Dejan
    CANCER RESEARCH, 2022, 82 (04)
  • [6] Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve.
    Chia, Stephen K. L.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Juric, Dejan
    Bachelot, Thomas
    Rugo, Hope S.
    Ciruelos, Eva M.
    Lerebours, Florence
    Prat, Aleix
    Akdere, Murat
    Arce, Christina
    Gu, Ennan
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] BYLieve: A phase 2 study of alpelisib with fulvestrant or letrozole for treatment of PIK3CA mutant, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase (CDK)4/6 inhibitor therapy
    Rugo, Hope S.
    Turner, Nicholas
    Chia, Stephen
    Ciruelos, Eva
    Nienstedt, Carolyn
    Ridolfi, Antonia
    Kong, Oliver
    Sankaran, Banu
    Juric, Dejan
    CANCER RESEARCH, 2018, 78 (04)
  • [8] Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial
    Turner, Nick
    Rugo, Hope S.
    Ciruelos, Eva M.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Lerebours, Florence
    Prat, Aleix
    Bachelot, Thomas
    Chia, Stephen
    Balbin, Alejandro
    Joshi, Mukta
    Roux, Estelle
    Arce, Christina H.
    Akdere, Murat
    Juric, Dejan
    CANCER RESEARCH, 2022, 82 (04)
  • [9] BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy.
    Rugo, Hope S.
    Bianchi, Giulia Valeria
    Chia, Stephen K. L.
    Turner, Nicholas C.
    Juric, Dejan
    Jacot, William
    Borrego, Manuel Ruiz
    Chap, Linnea I.
    Brown-Glaberman, Ursa Abigail
    Nienstedt, Carolyn C.
    Sophos, Nikos
    Ridolfi, Antonia
    Lin, Chinjune
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Clinical characteristics and outcome of PIK3CA mutated hormone receptor positive (HR plus ), human epidermal growth factor 2 negative (HER2-), advanced breast cancer (BC) treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i): Real world data
    Plavetic, Natalija Dedic
    Cular, Katarina
    Krizic, Marija
    Popovic, Marina
    Plestina, Stjepko
    Silovski, Tajana
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345